Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Epigenetic biomarkers in prostate cancer: current and future uses|
|Citation:||Cancer Letters, 2014; 342(2):248-256|
|Publisher:||Elsevier Sci Ireland Ltd|
|Karen Chiam, Carmela Ricciardelli and Tina Bianco-Miotto|
|Abstract:||Epigenome alterations are characteristic of nearly all human malignancies and include changes in DNA methylation, histone modifications and microRNAs (miRNAs). However, what induces these epigenetic alterations in cancer is largely unknown and their mechanistic role in prostate tumorigenesis is just beginning to be evaluated. Identification of the epigenetic modifications involved in the development and progression of prostate cancer will not only identify novel therapeutic targets but also prognostic and diagnostic markers. This review will focus on the use of epigenetic modifications as biomarkers for prostate cancer.|
|Keywords:||Animals; Humans; Prostatic Neoplasms; Genetic Predisposition to Disease; Histones; MicroRNAs; Tumor Markers, Biological; Prognosis; Predictive Value of Tests; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Phenotype; Male; Genetic Testing|
|Rights:||© 2012 Elsevier Ireland Ltd. All rights reserved.|
|Appears in Collections:||Obstetrics and Gynaecology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.